Brain tumor patients who are uninsured or use Medicaid stay hospitalized longer and develop more medical complications than those with private insurance, University of Florida Health researchers have found.
Brain tumor patients who are uninsured or use Medicaid stay hospitalized longer and develop more medical complications than those with private insurance, University of Florida Health researchers have found.
The uninsured and Medicaid patients were also at greater risk of developing a new medical condition in the hospital and 25% more likely to die during their stay, according to a study published online February 18 in the journal Neurosurgery. Those same patients ended up in a nursing home, rehabilitation center or hospice more frequently than people who had private insurance. For the study, the researchers analyzed nationwide data from 566,346 hospital admissions involving brain tumor cases between 2002 and 2011.
People who are uninsured or use Medicaid also are less likely to benefit from early detection of brain tumors because they have less access to health care than those with private insurance, said Dr Kristopher G. Hooten, a resident in the UF College of Medicine’s department of neurosurgery and the study’s lead author.
Link to the press release by The University of Forida:
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More